Table 2. Treatment effects of sacubitril/valsartan on selected vital signs and laboratory values across two SBP categories from baseline to month six.
| SBP < 100 mmHg (n = 47) | SBP ≥ 100 mmHg (n = 70) | P-value | ||||
| Difference (95% CI) | P-value | Difference (95% CI) | P-value | |||
| SBP: systolic blood pressure. | ||||||
| Left ventricular ejection fraction, % | 10.8 (7.7–14.0) | < 0.001 | 14.0 (11–17.0) | < 0.001 | 0.12 | |
| Left ventricular end-diastolic diameter, mm | -3.3 (-5.6–-1.1) | 0.004 | -6.5 (-8.5–-4.5) | < 0.001 | 0.03 | |
| Left atrium diameter, mm | -3.1 (-5.4–-0.9) | 0.008 | -3.5 (-5.5–-2.0) | < 0.001 | 0.63 | |
| N-terminal pro-B-type natriuretic peptide, pg/mL | -1627.5 (-2638.4–-763.6) | < 0.001 | -1340.1 (-1988.0–-855.1) | < 0.001 | 0.75 | |
| SBP, mmHg | 7.5 (3.4–11.6) | 0.001 | -11.5 (-16.0–-7.0) | < 0.001 | < 0.001 | |
| Diastolic blood pressure, mmHg | -2.0 (-5.0–1.5) | 0.134 | -7.0 (-10.5–-4.0) | < 0.001 | 0.02 | |
| Heart rate, beats/min | -10.5 (-18.0–-4.0) | 0.025 | -16.5 (-20.0–-13.5) | < 0.001 | 0.15 | |
| Estimated glomerular filtration rate, mL/min per 1.73 m2 |
7.5 (-0.3–15.3) | 0.059 | 7.6 (1.8–14.1) | 0.015 | 0.69 | |
| Serium potassium, mmol/L | 0.1 (-0.0–0.3) | 0.095 | -0.1 (-0.3–0.1) | 0.203 | 0.04 | |